• Latest Posts

UPDATE: FDA Lifts Hold on Adaptimmune’s Rare Cancer Trials

TCR and Checkpoint inhibitors: A Match made in Heaven for Blood Cancer

Adaptimmune Revises TCR Protocol following Phase I/IIa Failure

7 Trendy European Biotechs Listed on the NASDAQ in 2016

Here’s my Chat with the CBO of Immunocore, the Only EU Biotech to have ever raised €300M in one Round

ADVERTISEMENT

Leading TCR Immuno-oncology Biotech shows Promising Results against Cancer

The 9 EU-based Billion-Euro Biotechs you Should (really) Know

Adaptimmune Clinical Trials full-steam ahead with GSK investment!

Adaptimmune’s TCR Therapy Proves its Superiority over its Immuno-oncology Competitors

Immunocore Skyrocketed by Europe’s Largest Private Biotech Financing Ever

ADVERTISEMENT